Primary Biliary Cirrhosis Associated with Systemic Sclerosis: Diagnostic and Clinical Challenges

Cristina Rigamonti, 1 Dimitrios P. Bogdanos, 2 Maria G. Mytilinaiou, 2 Daniel S. Smyk, 2 Eirini I. Rigopoulou, 3 and Andrew K. Burroughs 4

1 Department of Clinical and Experimental Medicine, Università del Piemonte Orientale "A. Avogadro", 28100 Novara, Italy
2 Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, Denmark Hill Campus, London SE5 9RS, UK
3 Department of Medicine, University of Thessaly Medical School, Mezourlo, 41110 Larissa, Greece
4 The Sheila Sherlock Liver Centre and University Department of Surgery, Royal Free Hospital, London NW3 2QG, UK

Correspondence should be addressed to Dimitrios P. Bogdanos, dimitrios.bogdanos@kcl.ac.uk

Received 3 June 2011; Accepted 7 September 2011

Academic Editor: Laura K. Hummers

Copyright © 2011 Cristina Rigamonti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Patients with primary biliary cirrhosis (PBC) often have concurrent limited systemic sclerosis (SSc). Conversely, up to one-fourth of SSc patients are positive for PBC-specific antimitochondrial antibodies (AMA). The mechanisms responsible for the co-occurrence of these diseases are largely unknown. Genetic, epigenetic, environmental, and infectious factors appear to be important for the pathogenesis of the disease, but the hierarchy of events is not well defined. Patients with SSc and PBC have an increased morbidity and mortality compared with the general population, but whether the presence of both diseases in an affected individual worsens the prognosis and/or outcome of either disease is not clear. Some case reports suggested that the presence of SSc in PBC patients is associated with a more favorable prognosis of the liver disease, whereas others report an increased mortality in patients with PBC and SSc compared to patients with PBC alone. This paper discusses the features of patients with PBC-associated SSc. Our aims are to clarify some of the pathogenetic, diagnostic, and clinical challenges that are currently faced in the routine management of these patients. We also intend to provide some practical hints for practitioners that will assist in the early identification of patients with PBC-associated SSc.

1. Introduction

1.1. Primary Biliary Cirrhosis. Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by immune-mediated chronic nonsuppurative cholangitis that mainly affects interlobular and septal bile ducts [1–3]. PBC is a rare disease with prevalence ranging from 28 to 402 per million [4], which is highly variable based on geographical location. PBC primarily affects middle aged women [5]. Several reports indicate that the incidence and prevalence of PBC is increasing in the UK, USA, Finland, and Australia [4–7]. PBC often occurs in association with other autoimmune conditions [1–3]. The serological hallmark of PBC is the presence of high-titre serum antimitochondrial autoantibodies (AMA), usually existing in 90–95% of patients with PBC [1–3, 8–16]. The presence of AMA in asymptomatic patients is usually indicative of eventual PBC development [17]. These autoantibodies specifically recognize lipoylated domains within components of the 2-oxoacid dehydrogenase family of enzymes, particularly the E2 component of the pyruvate dehydrogenase complex, located within the inner mitochondrial membrane [1–3, 8–12]. Indirect immunofluorescence using rodent liver, kidney, and stomach sections as substrate is still the most widely used screening assay for AMA in the routine setting [18]. Other techniques such as immunoblotting and ELISA have a higher sensitivity, and the use of cloned mitochondrial antigens and bead assay testing systems allows for the identification of AMA in the sera of patients previously defined as AMA negative [19]. Additionally, PBC-specific antinuclear autoantibodies...
such as the presence of autoreactive T cells and serum auto-

2.1. Epidemiology. PBC has been considered as the most

2. PBC-SSc

2.1. Epidemiology. PBC has been considered as the most

2.2. Immunopathogenesis. Despite the scarcity of case reports

and infectious
factors appear to be important for the induction of the underlying autoimmune pathology, but the hierarchy of events and the close interplay of these factors are not well defined.

The association between PBC and SSc has been largely based on reports indicating the presence of autoantibodies related to SSc in patients with PBC and vice versa. Autoantibodies which characterize limited cutaneous SSc (lcSSc) include anti-centromere antibodies (ACA), anti-Th/To, anti-U1-RNP, and PM/Scl. Diffuse cutaneous SSc (dcSSc) is characterized by anti-Scl 70 antibody (anti-topoisomerase I antibody, TOPO), anti-RNA polymerase III, and anti-U3-RNP [71]. Severe lung disease is the hallmark of anti-TOPO-positive dcSSc patients. DcSSc patients with anti-RNA polymerase III have the most severe skin disease and the highest frequency of renal crisis. Patients with the nucleolar antibody anti-U3-RNP have dcSSc with multiorgan involvement [71].

The autoimmune basis of association between PBC and SSc was first established by the presence of AMA in approximately 5% of patients with scleroderma and ACA in one-quarter of patients with PBC [55]. A positive ACA is reported in 9–30% of PBC patients [59, 72–75] and in 22–25% of all SSc patients, almost all of which have lcSSc. Conversely, up to 25% of SSc patients are AMA positive, but the high prevalence rates of AMA are probably secondary to referral bias and overestimate the frequency of AMA in SSc [76–79]. Another interesting point which needs attention is that of studies reporting a relatively high prevalence of AMA negative PBC in patients with SSc or other autoimmune diseases [51, 80] the autoantibody profile of SSc patients with AMA-negative PBC may require the use of highly sensitive immunoassays for the detection of AMA. It has been shown that such assays are able to detect AMA in serum samples from SSc patients characterized as AMA negative by indirect immunofluorescence, and this may be the case for other PBC-specific autoantibodies, such as ANA specific for sp100 [11, 12, 50].

ACA positivity is greater in PBC-SSc than in either disease in isolation, but there is no cross-reactivity between mitochondrial and centromere antigens [81]. Because ACA have been detected not only in SSc but also in other autoimmune diseases [82–85] including PBC [72, 86], the clinical significance of ACA in PBC has been the focus of ongoing research. Three major centromere antigens have been recognized: centromere protein A (CENP-A, 18 kD polypeptide), centromere protein B (CENP-B, 80 kD polypeptide), and centromere protein C (CENP-C, 140 kD polypeptide). One study attempted to identify the major epitope of ACA in sera obtained from patients with PBC and to classify the correlation between the presence of ACA epitope and the clinical features in patients with PBC [87]. The serological results obtained were compared with clinical features of lcSSc in PBC. Forty-one patients with PBC were studied: 10 out of 16 (63%) patients with ACA (all anti-CENP-A) had one or more lcSSc feature. The higher incidence of Raynaud’s phenomenon seen in ACA-positive patients with PBC than that in ACA-negative patients with PBC suggested a close association of the presence of ACA with clinical features of lcSSc in patients with PBC [87]. From the results of this study, it was proposed that there is a subset of PBC patients with scleroderma who are ACA positive and differ from both ACA-negative PBC-SSc and ACA-negative PBC non-SSc patients, based on their clinical features and ACA epitope reactivity [87].

Over the past two years, a tremendous amount of data has come available as to the genetics underlying PBC and SSc. In regards to SSc, several HLA and non-HLA regions have been identified [88], with HLA regions showing variability among ethnic groups. Positive HLA associations in whites and Hispanics include HLA-DRB1*1104, DQA1*0501, DQB1*0301, HLA-DRB1*0804, DQA1*0501, DQB1*0301. Negative associations in those groups included DRB1*0701, DQA1*0201, DQB1*0202, and DRB1*1501 [89]. Positive HLA associations in African Americans included HLA-DRB1*0804,

| Table 1: Features demographic, immunological and genetic features of primary biliary cirrhosis (PBC) and systemic sclerosis (SSc). |
|---------------------------------------------------------------|
| **PBC**                                                      | **SSc**                                                      |
| Prevalence (highly variable geographically)                  | 28–402/million                                              |
| Incidence (highly variable geographically)                   | 2.3–27/million                                              |
| Male to female ratio                                         | 1:8                                                         |
| Peak frequency age                                           | 53 years                                                    |
| Autoantibodies                                              | AMA, ANA                                                    |
| Genes (positive associations)                                | Non-HLA: IRF5, STAT4, SPIB,                                |
|                                                            | HLA: DRB1, DQA1, DQB1, DQA2                                 |
|                                                            | Non-HLA: STAT4, IRF5, BANK1, TNSF4,                         |
|                                                            | TBX21, IL-23R, and C8orf13-BLK                               |
| AMA, anti-mitochondrial antibody; ANA, anti-nuclear antibody; ACA, anti-centromere antibody. |
DQA1*0501, and DQ8B1*0301 [89]. That study also noted that ACA positivity was closely associated with HLA-DQB1*0501 [89], and another study found an association between TOPO positivity and HLA-DR8B1*1104 [90]. A smaller study of a Spanish cohort showed similar HLA findings to those noted above [90]. Several non-HLA regions have also been identified in SSc. These include STAT4 [88, 91–94], IRF5 [88, 95, 96], BANK1 [97, 98], TNSF4 [99], Tbx21 [92], IL-23R [100], and C8orf13-BLK [101] among others [88]. As with SSc, several HLA and non-HLA regions have been identified in PBC. HLA regions include DRB1, DQ8A1, DQ8B1, and DQA2 [102, 103]. Non-HLA regions include IRF5, STAT4, SPIB, IKZF3-ORMDL3, IL12A, IL12RB, MME1, DENNDB1, CD80, IL7, CXCR5, TNFRSF1A, CLEC16A, and NKF81 [104–106]. Interestingly, PBC and SSc have several genes in common: HLA-DRB1, DQA1, DQB1, IRF5, and STAT4, although it should be noted that DR11, which is positively associated with SSc, is considered protective in PBC [88, 105].

Infectious agents have been implicated in the pathogenesis of both SSc and PBC. A number of organisms, such as E. coli, have been strongly associated with PBC [22, 107, 108], but not with SSc. Helicobacter pylori and Chlamydia have been implicated in both conditions [109–119]; however, some studies indicate the Chlamydia is not involved [72, 120, 121]. It is possible that certain infectious organisms contribute to the development of PBC or SSc in isolation and that other organisms induce the disease in both conditions.

2.3. Screening and Diagnosis of PBC in SSc Patients and Vice Versa. Given the overlap between PBC with SSc and vice versa, including ACA positivity in PBC patients and AMA positivity in SSc patients, the major challenge remains to clarify which screening method would be best for early diagnosis of the associated conditions.

Firstly, routine screening for PBC-specific antibodies in patients with SSc needs to be further refined. Recently, Norman et al. investigated the presence of antibodies against PBC disease-specific mitochondrial antigens and antibodies against the sp100 nuclear body antigen in 52 patients with SSc, using two commercially available ELISAs [79]. In that study, 13% of cases were positive for AMA and 2% for ANA (anti-sp100), and one patient (2%) was diagnosed with symptomatic PBC [79]. These figures were reproduced by Mytilinaiou et al., who confirmed 13.5% positive results with ELISA testing for antibodies against PBC disease-specific mitochondrial antigens in 37 SSc patients [79]. However, this was not confirmed with the conventional indirect immunofluorescence based on unfixed rodent kidney, liver, stomach tissue sections, or HEP-2 cells as antigenic substrates, and none of the ELISA-positive patients showed features of PBC [78]. It remains to be clarified whether ELISA testing is less specific with false positive results or that it simply represents a more sensitive method with respect to indirect immunofluorescence, which should currently remain the technique of choice.

Nevertheless, the presence of AMA can precede clinical symptoms of PBC. Indeed, Mitchison et al. and Metcalf et al. showed that the vast majority of AMA-positive subjects have typical histological features of PBC despite being asymptomatic with normal biochemistry [17, 122]. Furthermore, the study by Prince et al. suggested that 36% of initially asymptomatic PBC patients would become symptomatic within a median time of 5 years [123]. Thus, AMA-positive SSc cases require immediate attention and close, long-term monitoring for early detection of symptoms, signs, and liver biochemistry suggestive of chronic cholestatic liver disease. Routine followup of AMA-positive SSc patients should include liver tests (alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transpeptidase, alkaline phosphatase, albumin, bilirubin, international normalized ratio), thyroid function, and possibly an annual ultrasound abdominal scan. Transient elastography of the liver has been used to assess biliary fibrosis in patients with PBC [124]. This test is emerging as a useful screening tool to detect undiagnosed chronic liver disease in apparently healthy subjects [125]. Whether patients with SSc, who are tested positive for PBC-specific AMA, need regular checks with transient elastography or more common tests, such as liver ultrasound, needs to be evaluated in large prospective multicentre studies. Currently, there is no evidence that either of these would be of value. Figure 1 illustrates the diagnostic and screening algorithm for PBC in SSc patients.

Screening PBC patients for ACA is not mandatory but can be considered, especially in the presence of disease-related symptomatology. Nakamura et al. reported that, in PBC patients, ACA positivity was significantly associated with more severe ductular pathology on liver histology and was a significant risk factor for the development of portal hypertension [126]. In another study, ACA-positive PBC patients without clinical features of SSc were shown to have similar symptoms and signs at diagnosis [49]. Although ACA positivity is not pathognomonic of SSc, it is associated with an increased risk of developing connective tissue disease [127]. One review [128] reported a sensitivity of 32% (17–56%) for SSc and 57% (32–96%) for lcSSc and specificity of at least 93%, while ACA positivity was present in 5% of patients with other connective tissue diseases and less than 1% of disease-free controls. Since ACA could be predictive of rheumatic disorders, it has been suggested that an assessment of PBC patients should always include screening for SSc-related symptoms, such as Raynaud’s phenomenon and CREST-related symptoms (calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) [129]. The use of nailing videocapillaroscopy in patients suspected of having connective tissue disease may be a useful indicator. Some evidence suggests that this assessment can be useful for the diagnostic and/or clinical management of patients with PBC and suspected SSc. Experimental and clinical observation suggests that patients with PBC have endothelial dysfunction [130]. In an interesting study, nailfold videocapillaroscopy abnormalities were found in 91% of patients with PBC, and capillary alterations characteristic of SSc was found in 54% [131]. Eleven out of the 22 PBC patients (50%) had extrahepatic signs of connective tissue disease with most being related to SSc, while patients with other types of chronic liver disease did not present with rheumatic
2.4. Clinical Presentation and Prognosis. In approximately 60% of the cases, the clinical presentation of SSc precedes that of PBC. The demographics of the disease in patients with overlapping features are not well defined. For example, it is not clear whether in the PBC-SSc group the diagnosis of PBC occurs at a lower age than that in patients with PBC alone. In a study of 43 PBC-SSc patients, the median age at diagnosis of PBC made after SSc diagnosis was lower (46.1 years) than in PBC diagnosed before SSc (51.1 years). This was lower than the diagnosis in PBC alone, with a median age of 53.2 years at diagnosis [49]. The different age at diagnosis in the PBC-SSc patients, compared to patients with PBC alone, was probably due to the effect of lead time bias (i.e., screening for PBC in SSc patients and thus early diagnosis of asymptomatic PBC, since 56% presented with SSc alone).

PBC-SSc patients were reported to have a higher incidence of a first episode of spontaneous bacterial peritonitis and sepsicaemia during followup with respect to patients with PBC alone. This is likely due to an increased risk of infection due to immune abnormalities and organ system manifestations associated with SSc [132].

Both SSc and PBC are associated with increased morbidity and mortality compared with the general population [123, 133–139]. Among the disease-related causes of mortality in SSc patients, pulmonary fibrosis, pulmonary arterial hypertension, and cardiac causes (mainly heart failure and arrhythmias) are reported to account for the majority of deaths. The most frequent non-SSc-related causes of death are infections, malignancies, and cardiovascular causes [140]. In PBC patients, liver-related causes account for roughly 50% of deaths, whereas cardio- and cerebrovascular causes together with malignancies are responsible for the non-liver-related deaths [139, 141]. Some case reports [62, 142] suggest that PBC in association with SSc is associated with a more favourable prognosis than PBC alone, whereas others reported increased mortality due to SSc [143]. In the study which included 43 PBC-SSc patients, liver disease had a slower progression in PBC-SSc compared to matched patients with PBC alone. A lower rate of liver transplantation and liver-related deaths was demonstrated in PBC-SSc patients compared to patients with PBC alone, and these differences were not due to earlier SSc-related deaths [49]. However, the improvement in liver-related survival in the PBC-SSc cohort was outweighed by an increase in
non-liver-related deaths due to SSc, and, thus, overall survival was not different in PBC-SSc patients and those with PBC alone [49]. These data emphasize the importance of comorbidity in PBC. More data on the outcome of patients with PBC and PBC with SSc are needed. If patients with PBC and SSc have a lower rate of liver transplantation and liver-related deaths compared to patients with PBC alone [49], it would be expected that patients with PBC and SSc-related ACA would also have better prognosis than their seronegative counterparts, but this does not appear to be the case [126]. It may be that the outcome of patients with ACA-positive PBC, who do not have SSc-related symptoms, differs from that of ACA-positive SSc and PBC overlap.

Prince and colleagues observed an increase in non-liver-related deaths in asymptomatic PBC, even with a reduced liver-related mortality, in comparison with symptomatic PBC [123]. Since the causes of death in PBC-SSc patients are mainly due to SSc and not to liver disease, these patients may need different prognostic models in order to better predict their liver-related survival. Prognostic models for PBC alone may not be applicable for PBC associated with SSc or for other associated autoimmune diseases to assess the risk of liver-related mortality and the need for liver transplantation.

2.5. Therapy. All PBC patients with abnormal liver biochemistry should be considered for specific therapy. UDCA at the dose of 13–15 mg/kg/day on a long-term basis is currently considered the mainstay of therapy for PBC [18]. In the early stages of PBC, UDCA protects injured cholangiocytes against the toxic effects of bile acids. In later stages of the disease, UDCA stimulates impaired hepatocellular secretion, mainly by posttranscriptional mechanisms [144]. In addition, stimulation of ductular alkaline cholerisis and inhibition of bile acid-induced hepatocyte and cholangiocyte apoptosis are included among the beneficial effects of UDCA in PBC [144]. UDCA has been demonstrated to markedly decrease serum bilirubin, alkaline phosphatase, γ-glutamyl transpeptidase, cholesterol, and immunoglobulin M levels and to ameliorate histological features in patients with PBC in comparison to placebo treatment [145–149]. However, no significant effects on fatigue or pruritus were observed in these large trials nor were effects on survival [150]. Favorable long-term effects of UDCA are observed in patients with early disease and in those with a good biochemical response, which should be assessed after one year from start of treatment [18]. A good biochemical response after one year of UDCA treatment is currently defined by a serum bilirubin ≤1 mg/dL (17 μmol/L), alkaline phosphatase ≤3x ULN, and aspartate aminotransferase ≤3x ULN, according to the “Paris criteria” [151]. The “Barcelona criteria” indicates a good response with a 40% decrease or normalization of serum alkaline phosphatase [152].

Whether treatment with UDCA has an effect on the symptoms and the outcome of SSc remains poorly understood. Prospective studies of patients with PBC-associated SSc who are followed-up for many years under UDCA treatment are needed to address this issue.
The treatment of SSC is complex and may include drugs with hepatotoxic potential. For example, the use of endothelin-1 receptor antagonist bosentan, which is the treatment of choice for SSC-related pulmonary artery hypertension, has been associated with increased risk of elevated aminotransferases [153–155]. When PBC is present, the management of SSC patients is more challenging, as this autoimmune liver disease may pose further risk factors or unwanted complications. Whichever therapy is to be implemented, it is recommended that collaboration takes place between specialists responsible for the care of these patients.

3. Conclusions

The association of SSC and PBC is a rare but intriguing autoimmune syndrome which challenges the expertise and interests of hepatologists and rheumatologists in terms of early diagnosis and shared management. A major effort should be made for continuing collaborative research in this field aimed at achieving a better understanding of the immunopathogenesis, genetic background, and demographic features of patients at higher risk of developing the associated conditions. These findings may also contribute to the development of specific protocols for preventing development and evolution of the two associated diseases.

Abbreviations

ACA: Anticentromere antibody
AMA: Antimitochondrial antibody
ANA: Antinuclear antibody
CENP-A: Centromere protein A
CENP-B: Centromere protein B
CENP-C: Centromere protein C
dcSSc: Diffuse cutaneous systemic sclerosis
ELISA: Enzyme-linked immunosorbent assay
lcSSc: Limited cutaneous systemic sclerosis
PBC: Primary biliary cirrhosis
SSc: Systemic sclerosis
Anti-TOPO: Anti-topoisomerase (anti-Scl-70) antibody
UDCA: Ursodeoxycholic acid
ULN: Upper limit of normal.

Authors’ Contribution

D. P. Bogdanos and A. K. Burroughs are equally contributed to the paper.

Conflict of Interest

None of the authors has a conflict of interest to declare.

References

[1] M. M. Kaplan and M. E. Gershwin, “Primary biliary cirrhosis,” The New England Journal of Medicine, vol. 353, no. 12, pp. 1261–1273, 2005.

[2] S. Hohenester, R. P. J. Oude-Elferink, and U. Beuers, “Primary biliary cirrhosis,” Seminars in Immunopathology, vol. 31, no. 3, pp. 283–307, 2009.

[3] J. Neuberger, “Primary biliary cirrhosis,” The Lancet, vol. 350, no. 9081, pp. 875–879, 1997.

[4] H. Rautiainen, V. Salomaa, S. Niemela et al., “Prevalence and incidence of primary biliary cirrhosis are increasing in Finland,” Scandinavian Journal of Gastroenterology, vol. 42, no. 11, pp. 1347–1353, 2007.

[5] O. E. W. James, R. Bhopal, D. Howel, J. Gray, A. D. Burt, and J. V. Metcalf, “Primary biliary cirrhosis once rare, now common in the United Kingdom?” Hepatology, vol. 30, no. 2, pp. 390–394, 1999.

[6] W. R. Kim, K. D. Lindor, G. R. Locke et al., “Epidemiology and natural history of primary biliary cirrhosis in a U.S. community,” Gastroenterology, vol. 119, no. 6, pp. 1631–1636, 2000.

[7] S. Sood, P. J. Gow, I. M. Christie, and P. W. Angus, “Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations,” Gastroenterology, vol. 127, no. 2, pp. 470–475, 2004.

[8] D. P. Bogdanos, H. Baum, and D. Vergani, ”Antimitochondrial and other autoantibodies,” Clinics in Liver Disease, vol. 7, no. 4, pp. 759–777, 2003.

[9] W. Bernal, F. Meda, Y. Ma, D. P. Bogdanos, and D. Vergani, ”Disease-specific autoantibodies in patients with acute liver failure: the King’s College London experience,” Hepatology, vol. 47, no. 5, pp. 1096–1097, 2008.

[10] D. P. Bogdanos and L. Komorowski, “Disease-specific autoantibodies in primary biliary cirrhosis,” Clinica Chimica Acta, vol. 412, no. 7-8, pp. 502–512, 2011.

[11] C. Dähnrich, A. Pares, L. Caballeria et al., “New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies,” Clinical Chemistry, vol. 55, no. 5, pp. 978–983, 2009.

[12] H. Liu, G. L. Norman, Z. Shums et al., ”PBC Screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis,” Journal of Autoimmunity, vol. 35, no. 4, pp. 436–442, 2010.

[13] Y. Ma, M. G. Thomas, M. Okamoto et al., ”Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule,” Journal of Immunology, vol. 169, no. 1, pp. 277–285, 2002.

[14] E. I. Rigopoulou, E. T. Davies, D. P. Bogdanos et al., ”Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis,” Liver International, vol. 27, no. 9, pp. 1226–1231, 2007.

[15] D. Vergani and D. P. Bogdanos, ”Positive markers in AMA-negative PBC,” American Journal of Gastroenterology, vol. 98, no. 2, pp. 241–243, 2003.

[16] L. Wen, Y. Ma, D. P. Bogdanos et al., ”Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity,” Current Molecular Medicine, vol. 1, no. 3, pp. 379–389, 2001.

[17] J. V. Metcalf, H. C. Mitchison, J. M. Palmer, D. E. Jones, M. F. Bassendine, and O. F. W. James, “Natural history of early primary biliary cirrhosis,” The Lancet, vol. 348, no. 9039, pp. 1399–1402, 1996.

[18] European Association for the Study of the Liver, ”EASL Clinical Practice Guidelines: management of cholestatic liver diseases,” Journal of Hepatology, vol. 51, no. 2, pp. 237–267, 2009.
D. Smyk et al., “Autoimmunity and environment: am I at risk?,” *Clinical Reviews in Allergy and Immunology*, In press.

D. Smyk, M. G. Mytilinaiou, E. I. Rigopoulou, and D. P. Bogdanos, “PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York,” *Disease Markers*, vol. 29, no. 6, pp. 337–344, 2010.

D. P. Bogdanos, H. Baum, F. Gunsar et al., “Extensive homology between the major immunodominant mitochondrial antigen in primary biliary cirrhosis and Helicobacter pylori does not lead to immunological cross-reactivity,” *Scandinavian Journal of Gastroenterology*, vol. 39, no. 10, pp. 981–987, 2004.

D. P. Bogdanos, A. Pares, H. Baum et al., “Disease-specific cross-reactivity between mimicking peptides of heat shock protein of mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis,” *Journal of Autoimmunity*, vol. 22, no. 4, pp. 353–362, 2004.

L. Muratori, D. P. Bogdanos, P. Muratori et al., “Susceptibility to thyroid disorders in hepatitis C,” *Clinical Gastroenterology and Hepatology*, vol. 3, no. 6, pp. 595–603, 2005.

D. Polymeros, D. P. Bogdanos, R. Day, D. Arioli, D. Vergani, and A. Forbes, “Does cross-reactivity between mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn’s disease?”, *Gastroenterology*, vol. 131, no. 1, pp. 85–96, 2006.

D. Vergani, D. P. Bogdanos, and H. Baum, “Unusual suspects in primary biliary cirrhosis,” *Hepatology*, vol. 39, no. 1, pp. 38–41, 2004.
"Clinical and immunological characterization of patients with systemic sclerosis overlapping primary biliary cirrhosis: a comparison with patients with systemic sclerosis alone," Journal of Dermatology, vol. 26, no. 1, pp. 18–22, 1999.

S. Akimoto, O. Ishikawa, H. Takagi, and Y. Miyachi, "Immunological features of patients with primary biliary cirrhosis (PBC) overlapping systemic sclerosis: a comparison with patients with PBC alone," Journal of Gastroenterology and Hepatology, vol. 13, no. 9, pp. 897–901, 1998.

B. Brzezińska-Kolarz, A. Undas, A. Dyczek, and J. Musial, "Reynolds syndrome: the combination of scleroderma and primary biliary cirrhosis. Case report," Polskie Archiwum Medycyny Wewnętrznej, vol. 105, no. 3, pp. 231–234, 2001.

A. A. Clarke, R. M. Galbraith, E. B. D. Hamilton, and R. Williams, "Rheumatic disorders in primary biliary cirrhosis," Annals of the Rheumatic Diseases, vol. 37, no. 1, pp. 42–47, 1978.

Y. Geffroy, R. Colin, and J. Hemet, "Primary biliary cirrhosis and scleroderma," Medecine et Chirurgie Digestives, vol. 2, no. 5, pp. 281–286, 1973.

H. D. Goring et al., "[Coincidence of scleroderma and primary biliary cirrhosis. Results of a systematic study of a dermatologic patient sample]," Der Hautarzt, vol. 49, pp. 361–366, 1998.

S. Maekawa, E. Yano, and S. Shintani, "A case of rheumatoid arthritis associated with progressive systemic sclerosis and primary biliary cirrhosis in the presence of various autoantibodies," Rymachi, vol. 32, no. 5, pp. 515–521, 1992.

B. Marasini, M. Gagetta, V. Rossi, and P. Ferrari, "Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients," Annals of the Rheumatic Diseases, vol. 60, no. 11, pp. 1046–1049, 2001.

F. C. Powell, A. L. Schroeter, and E. R. Dickson, "Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases," Quarterly Journal of Medicine, vol. 62, no. 237, pp. 75–82, 1987.

S. Sherlock and P. J. Scheuer, "Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients," Annals of the Rheumatic Diseases, vol. 60, no. 11, pp. 1046–1049, 2001.

F. C. Powell, R. K. Winkelmann, and F. Venencie-Lemarchand, "The antinuclear antibody: disease specificity and clinical significance," Mayo Clinic Proceedings, vol. 59, no. 10, pp. 700–706, 1984.

M. J. Chou, M. Y. Lai, S. L. Lee, and G. I. Tsay, "Reactivity of anti-mitochondrial antibodies in primary biliary cirrhosis and systemic sclerosis," Journal of the Formosan Medical Association, vol. 91, no. 11, pp. 1075–1080, 1992.

R. C. Gupta, J. R. Seibold, M. R. Krishnan, and J. C. Steigerwald, "Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis," Clinical and Experimental Immunology, vol. 58, no. 1, pp. 68–76, 1984.

M. G. Mytilinaiou and D. P. Bogdanos, "Primary biliary cirrhosis-specific autoantibodies in patients with systemic sclerosis," Digestive and Liver Disease, vol. 41, no. 12, pp. 916, 2009.

G. A. McCarty, J. R. Rice, M. L. Bembe, and F. A. Barada, "Anticentromere antibody: disease specificity and clinical significance," Mayo Clinic Proceedings, vol. 41, no. 10, pp. 916, 2009.

F. C. Powell, R. K. Winkelmann, and F. Venencie-Lemarchand, "The antinuclear antibody: disease specificity and clinical significance," Mayo Clinic Proceedings, vol. 59, no. 10, pp. 700–706, 1984.

M. J. Chou, M. Y. Lai, S. L. Lee, and G. I. Tsay, "Reactivity of anti-mitochondrial antibodies in primary biliary cirrhosis and systemic sclerosis," Journal of the Formosan Medical Association, vol. 91, no. 11, pp. 1075–1080, 1992.

R. C. Gupta, J. R. Seibold, M. R. Krishnan, and J. C. Steigerwald, "Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis," Clinical and Experimental Immunology, vol. 58, no. 1, pp. 68–76, 1984.

M. G. Mytilinaiou and D. P. Bogdanos, "Primary biliary cirrhosis-specific autoantibodies in patients with systemic sclerosis," Digestive and Liver Disease, vol. 41, no. 12, p. 916, 2009.

G. A. McCarty, J. R. Rice, M. L. Bembe, and F. A. Barada, "Anticentromere antibody: disease specificity and clinical significance," Mayo Clinic Proceedings, vol. 41, no. 10, pp. 916, 2009.

F. C. Powell, R. K. Winkelmann, and F. Venencie-Lemarchand, "The antinuclear antibody: disease specificity and clinical significance," Mayo Clinic Proceedings, vol. 59, no. 10, pp. 700–706, 1984.

M. J. Chou, M. Y. Lai, S. L. Lee, and G. I. Tsay, "Reactivity of anti-mitochondrial antibodies in primary biliary cirrhosis and systemic sclerosis," Journal of the Formosan Medical Association, vol. 91, no. 11, pp. 1075–1080, 1992.

R. C. Gupta, J. R. Seibold, M. R. Krishnan, and J. C. Steigerwald, "Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis," Clinical and Experimental Immunology, vol. 58, no. 1, pp. 68–76, 1984.

M. G. Mytilinaiou and D. P. Bogdanos, "Primary biliary cirrhosis-specific autoantibodies in patients with systemic sclerosis," Digestive and Liver Disease, vol. 41, no. 12, pp. 916, 2009.
variants," *Arthritis and Rheumatism*, vol. 26, no. 1, pp. 1–7, 1983.

[84] S. Miyawaki, H. Asanuma, S. Nishiyama, and Y. Yoshinaga, "Clinical and serological heterogeneity in patients with anticientromere antibodies," *Journal of Rheumatology*, vol. 32, no. 8, pp. 1488–1494, 2005.

[85] J. R. Seibold and M. C. Trontell, "Anticientromere antibody and primary pulmonary hypertension," *Journal of Rheumatology*, vol. 9, no. 4, pp. 607–609, 1982.

[86] D. Makinen, M. Fritzler, P. Davis, and S. Sherlock, "Anti-centromere antibodies in primary biliary cirrhosis," *Arthritis and Rheumatism*, vol. 26, no. 7, pp. 914–917, 1983.

[87] I. Shoji, T. Takagi, and R. Kasukawa, "Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis," *Internal Medicine*, vol. 31, no. 12, pp. 1348–1355, 1992.

[88] S. K. Agarwal and J. D. Reveille, "The genetics of scleroderma (systemic sclerosis)," *Current Opinion in Rheumatology*, vol. 22, no. 2, pp. 133–138, 2010.

[89] F. C. Arnett, P. Gourh, S. Shete et al., "Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls," *Annals of the Rheumatic Diseases*, vol. 69, no. 5, pp. 822–827, 2010.

[90] P. Gourh, F. C. Arnett, F. K. Tan et al., "Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis," *Annals of the Rheumatic Diseases*, vol. 69, no. 3, pp. 550–555, 2010.

[91] S. K. Agarwal, P. Gourh, S. Shete et al., "Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-1 positivity and pulmonary hypertension in systemic sclerosis," *Journal of Rheumatology*, vol. 36, no. 12, pp. 2715–2723, 2009.

[92] P. Gourh, S. K. Agarwal, E. Martin et al., "Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations," *Journal of Autoimmunity*, vol. 34, no. 2, pp. 155–162, 2010.

[93] G. M. Hirschfeld, X. Liu, C. Xu et al., "Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants," *The New England Journal of Medicine*, vol. 360, no. 24, pp. 2544–2555, 2009.

[94] P. T. Donaldson, A. Baragiotta, M. A. Heneghan et al., "HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study," *Hepatology*, vol. 44, no. 3, pp. 667–674, 2006.

[95] G. M. Hirschfeld, X. Liu, Y. Han et al., "Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis," *Nature Genetics*, vol. 42, no. 8, pp. 655–657, 2010.

[96] X. Liu, P. Invernizzi, Y. Lu et al., "Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis," *Nature Genetics*, vol. 42, no. 8, pp. 658–660, 2010.

[97] G. F. Mells, J. A. Floyd, K. I. Morley et al., "Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis," *Nature Genetics*, vol. 43, no. 4, pp. 329–332, 2011.

[98] A. K. Burroughs, I. J. Rosenstein, and O. Epstein, "Bacteriuria and primary biliary cirrhosis," *Gut*, vol. 25, no. 2, pp. 133–137, 1984.

[99] S. P. M. Fussey, S. T. Ali, J. R. Guest, O. F. W. James, M. F. Bassendine, and S. J. Yeaman, "Reactivity of primary biliary cirrhosis sera Escherichia coli dihydrolipoamide acetyltransferase (E2p): characterization of the main immunogenic region," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 87, no. 10, pp. 3987–3991, 1990.

[100] C. Grossman, Z. Dovrish, Y. Shoenfeld, and H. Amital, "Do infections facilitate the emergence of systemic sclerosis?" *Autoimmunity Reviews*, 2010.

[101] A. Gabrielli, E. V. Avvedimento, and T. Krieg, "Mechanisms of disease: scleroderma," *The New England Journal of Medicine*, vol. 360, no. 19, pp. 1989–2003, 2009.

[102] G. Macchia, A. Massone, D. Burroni, A. Covacci, S. Censini, and R. Rappuoli, "The Hsp60 protein of Helicobacter pylori: structure and immune response in patients with gastroduodenal diseases," *Molecular Microbiology*, vol. 9, no. 3, pp. 645–652, 1993.

[103] S. B. Randone, S. Guiducci, and M. M. Cerinic, "Systemic sclerosis and infections," *Autoimmunity Reviews*, vol. 8, no. 1, pp. 36–40, 2008.

[104] A. S. Abudkarim, L. M. Petrovic, W. R. Kim, P. Angulo, R. V. Lloyd, and K. D. Lindor, "Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae?" *Journal of Hepatology*, vol. 40, no. 3, pp. 380–384, 2004.

[105] H. Y. Liu, A. M. Deng, J. Zhang et al., "Correlation of Chlamydia pneumoniae infection with primary biliary cirrhosis," *World Journal of Gastroenterology*, vol. 11, no. 26, pp. 4108–4110, 2005.
[115] D. P. Bogdanos, A. Pares, J. Rodés et al., “Primary biliary cirrhosis specific antinuclear antibodies in patients from Spain,” American Journal of Gastroenterology, vol. 99, no. 4, pp. 763–765, 2004.

[116] H. O. Nilsson, M. Castedal, R. Olsson, and T. Wadström, “Detection of Helicobacter in the liver of patients with chronic cholestatic liver diseases,” Journal of Physiology and Pharmacology, vol. 50, no. 5, pp. 875–882, 1999.

[117] H. O. Nilsson, J. Taneera, M. Castedal, E. Glatz, R. Olsson, and T. Wadström, “Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis,” Journal of Clinical Microbiology, vol. 38, no. 3, pp. 1072–1076, 2000.

[118] I. Nilsson, I. Kornilov’ska, S. Lindgren, A. Ljungh, and T. Wadström, “Increased prevalence of seropositivity for non-gastric Helicobacter species in patients with autoimmune liver disease,” Journal of Medical Microbiology, vol. 52, no. 11, pp. 949–953, 2003.

[119] I. Nilsson, S. Lindgren, S. Eriksson, and T. Wadström, “Serum antibodies to Helicobacter hepaticus and Helicobacter pylori in patients with chronic liver disease,” Gut, vol. 46, no. 3, pp. 410–414, 2000.

[120] P. S. C. Leung, O. Park, S. Matsumura, A. A. Ansari, R. L. Coppell, and M. E. Gershwin, “Is there a relation between chlamydia infection and primary biliary cirrhosis?” Clinical and Developmental Immunology, vol. 10, no. 2–4, pp. 227–233, 2003.

[121] D. Taylor-Robinson, A. W. Sharif, N. S. Dhanjal, and S. D. Taylor-Robinson, “Chlamydia pneumoniae infection is an unlikely cause of primary biliary cirrhosis,” Journal of Hepatology, vol. 42, no. 5, pp. 779–780, 2005.

[122] H. C. Mitchison, M. F. Bassendine, and A. Hendrick, “Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?” Hepatology, vol. 6, no. 6, pp. 1279–1284, 1986.

[123] M. I. Prince, A. Chetwynd, W. L. Craig, J. V. Metcalf, and O. F. W. James, “Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort,” Gut, vol. 53, no. 6, pp. 865–870, 2004.

[124] C. Corpechot, A. El Naggar, A. Poujol-Robert et al., “Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC,” Hepatology, vol. 43, no. 5, pp. 1118–1124, 2006.

[125] D. Roulot, J. L. Costes, J. F. Buycott et al., “Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years,” Gut, 2010.

[126] M. Nakamura, H. Kondo, T. Mori et al., “Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis,” Hepatology, vol. 45, no. 1, pp. 118–127, 2007.

[127] P. Caramaschi, D. Biasi, T. Manzo, A. Carletto, F. Poli, and L. M. Barbana, “Anticentromere antibody—clinical associations. A study of 44 patients,” Rheumatology International, vol. 14, no. 6, pp. 253–255, 1995.

[128] G. Spencer-Green, D. Alter, and H. G. Welch, “Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies,” American Journal of Medicine, vol. 103, no. 3, pp. 242–248, 1997.

[129] J. Avouac, J. Fransen, U. A. Walker et al., “Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group,” Annals of the Rheumatic Diseases, vol. 70, no. 3, pp. 476–481, 2011.

[130] B. Marasini, C. Pipia, G. DeValle et al., “Vascular impairment in patients with primary biliary cirrhosis,” International Journal of Microcirculation, Clinical and Experimental, vol. 15, no. 2, pp. 75–79, 1995.

[131] V. Fonollosa, C. P. Simeón, L. Castells et al., “Morphologic capillary changes and manifestations of connective tissue diseases in patients with primary biliary cirrhosis,” Lupus, vol. 10, no. 9, pp. 628–631, 2001.

[132] M. Juárez, R. Misichia, and G. S. Alarcón, “Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomysitis,” Rheumatic Disease Clinics of North America, vol. 29, no. 1, pp. 163–184, 2003.

[133] M. Abu-Shakra and P. Lee, “Mortality in systemic sclerosis: a comparison with the general population,” Journal of Rheumatology, vol. 22, no. 11, pp. 2100–2102, 1995.

[134] C. Bryan, Y. Howard, P. Brennan, C. Black, and A. Silman, “Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK population,” British Journal of Rheumatology, vol. 35, no. 11, pp. 1122–1126, 1996.

[135] H. Jackson, M. Solayman-Dodaran, T. R. Card, G. P. Aithal, R. Logan, and J. West, “Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study,” Hepatology, vol. 46, no. 4, pp. 1131–1137, 2007.

[136] S. Jacobsen, P. Halberg, and S. Ullman, “Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma),” British Journal of Rheumatology, vol. 37, no. 7, pp. 750–755, 1998.

[137] T. C. Mahl, W. Shockcor, and J. L. Boyer, “Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years,” Journal of Hepatology, vol. 20, no. 6, pp. 707–713, 1994.

[138] H. C. Mitchison, M. R. Lucey, P. J. Kelly, J. M. Neuberger, R. Williams, and O. F. W. James, “Symptom development and prognosis in primary biliary cirrhosis: a study in two centers,” Gastroenterology, vol. 99, no. 3, pp. 778–784, 1990.

[139] R. P. Myers, A. A. M. Shaheen, A. Fong et al., “Epidemiology and natural history of primary biliary cirrhosis in a Canadian Health Region: a population-based study,” Hepatology, vol. 50, no. 6, pp. 1884–1892, 2009.

[140] A. J. Tyndall, B. Bannert, M. Vonk et al., “Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database,” Annals of the Rheumatic Diseases, vol. 69, no. 10, pp. 1809–1815, 2010.

[141] D. E. Jones, A. Al-Rifai, J. Frith, I. Patanwala, and J. L. Newton, “The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up,” Journal of Hepatology, vol. 53, no. 5, pp. 911–917, 2010.

[142] C. Pollak, E. Minar, B. Dragosics, and L. Marosi, “Primary biliary cirrhosis and scleroderma: long term benign course of a complex autoimmune disease,” Leber Magen Darm, vol. 15, no. 2, pp. 83–89, 1985.

[143] D. R. Beswick, G. Klatskin, and J. L. Boyer, “Asymptomatic primary biliary cirrhosis. A progress report on long-term follow-up and natural history,” Gastroenterology, vol. 89, no. 2, pp. 267–271, 1985.
[144] U. Beuers, “Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis,” *Nature Clinical Practice Gastroenterology and Hepatology*, vol. 3, no. 6, pp. 318–328, 2006.

[145] B. Combes, R. L. Carithers, W. C. Maddrey et al., “A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis,” *Hepatology*, vol. 22, no. 3, pp. 759–766, 1995.

[146] E. J. Heathcote, K. Cauch-Dudek, V. Walker et al., “The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis,” *Hepatology*, vol. 19, no. 5, pp. 1149–1156, 1994.

[147] K. D. Lindor, E. R. Dickson, W. P. Baldus et al., “Ursodeoxycholic acid in the treatment of primary biliary cirrhosis,” *Gastroenterology*, vol. 106, no. 5, pp. 1284–1290, 1994.

[148] A. Parés, L. Caballería, J. Rodes et al., “Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver,” *Journal of Hepatology*, vol. 32, no. 4, pp. 561–566, 2000.

[149] R. E. Poupon, B. Balkau, E. Eschwege, and R. Poupon, “A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group,” *The New England Journal of Medicine*, vol. 324, no. 22, pp. 1548–1554, 1991.

[150] J. Goulis, G. Leandro, and A. K. Burroughs, “Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis,” *The Lancet*, vol. 354, no. 9184, pp. 1053–1060, 1999.

[151] C. Corpechot, L. Abenavoli, N. Rabahi et al., “Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis,” *Hepatology*, vol. 48, no. 3, pp. 871–877, 2008.

[152] A. Parés, L. Caballería, and J. Rodés, “Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid,” *Gastroenterology*, vol. 130, no. 3, pp. 715–720, 2006.

[153] J. Avouac, O. Kowal-Bielecka, R. Landewé et al., “European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research,” *Annals of the Rheumatic Diseases*, vol. 68, no. 5, pp. 629–634, 2009.

[154] O. Kowal-Bielecka, R. Landewé, J. Avouac et al., “EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR),” *Annals of the Rheumatic Diseases*, vol. 68, no. 5, pp. 620–628, 2009.

[155] L. J. Rubin, D. B. Badesch, R. J. Barst et al., “Bosentan therapy for pulmonary arterial hypertension,” *The New England Journal of Medicine*, vol. 346, no. 12, pp. 896–903, 2002.